Donnerstag, 27. Oktober 2016

  • Pressemitteilung BoxID 64702

Fresenius and APP Pharmaceuticals Announce Clearance of APP Acquisition by U.S. Federal Trade Commission

(lifePR) (Bad Homburg/Schaumburg, ) Fresenius SE and APP Pharmaceuticals, Inc., have received confirmation that the U.S. Federal Trade Commission (FTC) has completed its review of the proposed acquisition of APP Pharmaceuticals by Fresenius Kabi, a business segment of Fresenius SE. The FTC granted early termination of the waiting period under the Hart-Scott-Rodino Act without conditions. The German antitrust authorities had already approved the acquisition.

On July 7, 2008, Fresenius had announced the acquisition of APP Pharmaceuticals, an important step in the growth strategy of Fresenius Kabi. With the FTC review complete, Fresenius and APP expect the transaction to close mid September 2008, subject to certain other customary closing conditions.

About Fresenius Kabi

Fresenius Kabi is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. Fresenius Kabi's core product range includes infusion solutions for fluid substitution, blood volume expansion and parenteral nutrition, as well as products for enteral nutrition. Furthermore, the company provides concepts for ambulatory health care and is focused on managing and providing home therapies. With its philosophy "Caring for life" and a comprehensive product portfolio, the company aims at improving the quality of life of patients all over the world. On June 30, 2008 the company had 18,323 employees. In 2007, Fresenius Kabi achieved sales of € 2,030 million and an operating profit of € 332 million. Fresenius Kabi AG is a 100 % subsidiary of the health care group Fresenius SE.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. This includes the risk that the transaction will not be consummated or on other terms. Neither Fresenius nor APP undertakes any responsibility to update the forward-looking statements in this release.


In connection with the proposed merger, Fresenius Kabi Pharmaceuticals Holding, Inc. and APP have filed relevant materials with the SEC, including a registration statement that contains a joint prospectus and information statement. Investors and security holders are urged to read these documents and any other relevant documents filed with the SEC, as well as any amendments or supplements to those documents, because they contain important information. Investors and security holders may obtain these documents free of charge at the SEC's website at Investors and security holders are urged to read the joint information statement/prospectus and the other relevant materials before making any investment decision with respect to the proposed merger.

Über Fresenius AG (SE)

Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care. In 2007, group sales were approx. € 11.4 billion. On June 30, 2008 the Fresenius Group had 117,453 employees worldwide. For more information visit the Company's website at .

Diese Pressemitteilungen könnten Sie auch interessieren

Frailty mit Ernährungsinterventionen verhindern

, Gesundheit & Medizin, Nutricia GmbH

Ernährungszustand und Gebrechlichkeit (Frailty) sind eng miteinander verbunden.1 Dementsprechend spielen Interventionen wie Ernährungsberatung,...

Gesunder Rücken im Schlaf – darauf sollten Sie achten

, Gesundheit & Medizin, Aktion Gesunder Rücken (AGR) e.V.

Rund ein Drittel unseres Lebens verbringen wir schlafend – die Wahl des richtigen Bettes sollte also wohl überlegt sein. Wer auf unpassenden...

Nutricia schreibt Förderpreis für medizinische Ernährungsforschung aus

, Gesundheit & Medizin, Nutricia GmbH

Die Nutricia GmbH schreibt in diesem Jahr zu Ehren der wissenschaftlichen Arbeit von Dr. Werner Fekl den mit 5.000 Euro Preisgeld dotierten Förderpreis...